High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma

American Journal of Hematology

Volumn 86, Issue 2, 2011, Pages 224-227

  Darda Bayraktar, Ulas ^a   Warsch, Sean ^a   Pereira, Denise ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCIUM; CREATININE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG OVERDOSE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 78851470021     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21922     Document Type: Letter

References (25)

1. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
2. Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
4. San Miguel JF, Sànchez J, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer 1989; 59: 113-118.
5. Cavo M, Galieni P, Zuffa E, et al. Prognostic variables and clinical staging in multiple myeloma. Blood 1989; 74: 1774-1780.
6. Tsuchiya J, Murakami H, Kanoh T, et al. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol 1994; 87: 832-834.
7. Kastritis E, Anagnosoppoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimens and the impact of novel agents. Haematologica 2007; 92: 546-549.
8. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
9. Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48: 1347.
10. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: Inhibition of NF-κ B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
11. Ray A, LaForge S, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA Box and RNA start site occlusion. Mol Cell Biol 1990; 10: 5736.
12. Chen YH, Desai P, Shiao RT, et al. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood 1996; 87: 314-323.
13. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment for resistant myeloma. Ann Intern Med 1986; 105: 8-11.
14. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
15. Friedenberg WR, Kyle RA, Knospe WH, et al. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171-175.
16. Glasmacher A, Haferlach T, Gorschlüter M, et al. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997; 11: S22-S26.
17. Sengul S, Zwizinski C, Simon EE, et al. Endocytosis of light chains induces cytokines through activation of NF-κB in human proximal tubule cells. Kidney Int 2002; 62: 1977-1988.
18. Keeling J, Herrera GA. The mesangium as a target for glomerulopathic light and heavy chains: Pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 2007; 153: 116-134.
19. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κ B1 precursor protein and the activation of NF-κ B. Cell 1994; 78: 773-785.
20. Richardson PG, Sonneveld P, Schuster MW, et al. Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
21. Mulkerin D, Remick S, Ramanathan R, et al. Adoseescalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function [abstract]. J Clin Oncol 2006; 24(18S). Abstract 2032.
22. Ludwig H, Adam Z, Hajek R, et al. Bortezomib-doxorubicin-dexamethasone (BDD) in patients with acute light chain induced renal failure in multiple myeloma. Final results of a phase II study. Blood 2009; 114:Abstract 3862.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
25. Axelrod L. Glucocorticoids. In: Kelley WN, Harris EDJr, Ruddy S, Sledge CB, editors. Textbook of Rheumatology, 4th ed. Philadelphia: WB Saunders; 1993. p 779.